Shots:
- The US FDA has approved Enoby (RGB-14-P) & Xtrenbo (RGB-14-X), biosimilar versions of Prolia & Xgeva (denosumab) for the treatment of bone & skeletal disorders
- Approval was based on extensive clinical data submitted by Hikma, incl. analytical, non-clinical & clinical studies, which showed comparable quality, efficacy, safety & immunogenicity of Enoby & Xtrenbo to reference denosumab
- Hikma & Richter entered a license & commercialization deal in Dec 2021, with Richter handling product development & manufacturing, while Hikma manages FDA registration & holds exclusive US commercialization rights
Ref: Gedeon Richter | Image: Gedeon Richter & Hikma Pharmaceuticals | Press Release
Related News:- Gedeon Richter Receives CHMP’s Positive Opinion for Junod and Yaxwer (Biosimilars, Prolia and Xgeva)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
